Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2), and Inflammatory cytokine (COX-1, COX-2, and Cytokine)

This target group represents a composite of critical mediators in the human inflammatory response, comprising the enzymes Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2), and various pro-inflammatory cytokines such as Tumor Necrosis Factor-alpha (TNF-α) and Interleukins (IL-1, IL-6). COX-1 is a constitutively expressed enzyme responsible for maintaining physiological functions like gastric mucosal integrity and platelet homeostasis, whereas COX-2 is an inducible enzyme that drives the synthesis of prostaglandins during injury or infection (StatPearls: NBK549790). Inflammatory cytokines are small signaling proteins that coordinate the recruitment and activation of immune cells, playing a central role in the pathogenesis of chronic inflammatory and autoimmune diseases (Nature Reviews Immunology, 2017). Pharmacological targeting of this group is a cornerstone of anti-inflammatory therapy, utilizing nonsteroidal anti-inflammatory drugs (NSAIDs) to inhibit COX activity and biologic agents to block cytokine signaling. While highly effective for pain management and treating conditions like rheumatoid arthritis, these interventions are associated with significant safety concerns, including gastrointestinal ulceration, cardiovascular risks, and increased susceptibility to infections (The Lancet, 2013).

Other names

PTGS1PTGS2Prostaglandin-endoperoxide synthasePro-inflammatory cytokineInflammatory mediatorTumor Necrosis Factor-alpha (TNF-α)Interleukin-1 (IL-1)Interleukin-6 (IL-6)

Inhibition of cyclooxygenase (COX) enzymes to reduce the production of pro-inflammatory prostaglandins and thromboxanes, combined with the antagonism or neutralization of pro-inflammatory cytokines to suppress the broader inflammatory signaling cascade (StatPearls: NBK549790; Nature Reviews Immunology, 2017).